AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
January 7, 2019
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company,
December 21, 2018
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
CAMBRIDGE, Mass. , Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company,  today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI).